Company Ocugen, Inc.

Stocks

OCGN

US67577C1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 12/06/2026 am IST			5-day change	1st Jan Change
1.220 ^USD	+2.52%		-10.95%	-9.63%

04/06	Ocugen, Inc. Announces Executive Changes, Effective May 29, 2026	CI
15/05	Ocugen Closes Offering of Senior Notes Due 2034	MT

Business description: Ocugen, Inc.

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.

Number of employees: 116

Sales by Activity: Ocugen, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Research, Development and Commercialization of its Novel Gene Therapies	-	-	60.36L	40.55L	44.13L

See all business segments

Geographical breakdown of sales: Ocugen, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
United States	-	-	60.36L	40.55L	44.13L

See all geographic segments

Executive Committee: Ocugen, Inc.

Manager	Title	Age	Since
Shankar Musunuri CEO	Chief Executive Officer	62	27/09/2019
Rita Johnson-Greene DFI	Director of Finance/CFO	-	09/02/2026
Mohamed Genead CTO	Chief Tech/Sci/R&D Officer	-	-
Jesse Simmers CTO	Chief Tech/Sci/R&D Officer	-	-
Arun Upadhyay CTO	Chief Tech/Sci/R&D Officer	44	01/12/2020

See OCUGEN, INC. governance

Composition of the Board of Directors: Ocugen, Inc.

Director	Title	Age	Since
Shankar Musunuri CHM	Chairman	62	27/09/2019
Uday Kompella BRD	Director/Board Member	59	01/09/2013
Junge Zhang BRD	Director/Board Member	59	01/09/2019
Kirsten Castillo BRD	Director/Board Member	53	05/04/2020
C. Satish Chandran BRD	Director/Board Member	70	05/06/2025
Blaise Coleman BRD	Director/Board Member	52	05/06/2025

Composition of the Board of Directors

Shareholders: Ocugen, Inc.

Name	Stocks	%	Valuation
Millennium Management LLC 5.044 %	1,70,74,584	5.044 %	24 M $
Vanguard Capital Management LLC 4.078 %	1,38,04,111	4.078 %	19 M $
Millennium Management LLC 4.055 %	1,37,27,192	4.055 %	19 M $
STATE STREET CORPORATION 2.857 %	96,70,191	2.857 %	13 M $
Marshall Wace LLP 2.379 %	80,52,350	2.379 %	11 M $

List of OCUGEN, INC. shareholders

Company details: Ocugen, Inc.

Ocugen, Inc.

11 Great Valley Parkway

19355, Malvern

http://www.ocugen.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OCUGEN, INC.	+2.52%	-10.95%	+5.17%	+166.32%	41Cr
LONZA GROUP AG	-1.40%	+0.12%	-14.73%	-12.58%	4.3TCr
REVOLUTION MEDICINES, INC.	+3.50%	-4.15%	+265.85%	+484.30%	3.17TCr
IQVIA HOLDINGS INC.	-0.61%	-3.11%	+14.00%	-12.36%	3.02TCr
BEONE MEDICINES AG	-1.27%	-7.02%	-0.82%	+20.47%	2.89TCr
CELLTRION, INC.	-0.66%	-5.84%	+7.59%	+12.76%	2.39TCr
MEDPACE HOLDINGS, INC.	+2.01%	+3.57%	+57.15%	+128.55%	1.36TCr
EUROFINS SCIENTIFIC SE	-1.65%	-1.08%	+7.92%	+7.56%	1.3TCr
ASCENDIS PHARMA A/S	+2.77%	-1.48%	-	-	1.34TCr
IONIS PHARMACEUTICALS, INC.	+0.68%	-1.74%	+103.98%	+81.60%	1.22TCr
Average	+0.59%	-2.89%	+49.57%	+97.40%	2.1TCr
Weighted average by Cap.	+0.15%	-2.41%	+53.50%	+92.73%